Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA.
Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of meningitis, sepsis and pneumonia in neonates in the United States. GBS also causes invasive disease in older infants, pregnant women, children and young adults with underlying medical conditions, and older adults. Resistance to lincosamides in the absence of erythromycin resistance is rare in GBS, but has been previously reported in clinical isolates, both on its own or in combination with resistance to streptogramins A and pleuromutilins (L/LSA/LSAP phenotypes).



To retrospectively screen the Active Bacterial Core surveillance (ABCs) GBS isolate collection for these phenotypes in order to identify the causal genetic determinants and determine whether their frequency is increasing.



Based on MIC data, 65 (0.31%) isolates susceptible to erythromycin (MIC ≤0.25 mg/L) and non-susceptible to clindamycin (MIC ≥0.5 mg/L) were identified among 21 186 GBS isolates. Genomic DNA was extracted and WGS was performed. The presence of 10 genes previously associated with LSA resistance was investigated by read mapping.



Forty-nine (75%) isolates carried the lsa (C) gene and expressed the LSAP phenotype, and 12 (18%) carried both the lnu (B) and lsa (E) genes and expressed the LSAP phenotype. The four remaining isolates were negative for all determinants investigated.



While the overall observed frequency of these phenotypes among our GBS isolates was quite low (0.31%), this frequency has increased in recent years. To the best of our knowledge, this is the first time the LSAP phenotype has been reported among GBS isolates from the USA.
Rollins School of Public Health, Emory University, Atlanta, GA, USA.|Centers for Disease Control and Prevention, Atlanta, GA, USA.
Paulina A
PA
Hawkins
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Caitlin S
CS
Law
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Benjamin J
BJ
Metcalf
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Sopio
S
Chochua
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Delois M
DM
Jackson
Weill Cornell Medical College, New York, NY, USA.
Lars F
LF
Westblade
Children's Healthcare of Atlanta, Atlanta, GA, USA.
Robert
R
Jerris
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Bernard W
BW
Beall
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Lesley
L
McGee
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D002981:Clindamycin / Q000494:pharmacology; D004224:Diterpenes / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D062665:Epidemiological Monitoring; D004917:Erythromycin / Q000494:pharmacology; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D055231:Lincosamides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010641:Phenotype; D011083:Polycyclic Compounds; D011247:Pregnancy; D013290:Streptococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D013292:Streptococcus agalactiae / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D025361:Streptogramins / Q000494:pharmacology; D014481:United States / Q000453:epidemiology; D055815:Young Adult; D000097567:Pleuromutilins
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D004224:Diterpenes; D004917:Erythromycin; D055231:Lincosamides; D011083:Polycyclic Compounds; D025361:Streptogramins; D000097567:Pleuromutilins